Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

NCT06281964 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: PLB1004
DRUG: Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab

Sponsor

Avistone Biotechnology Co., Ltd.